Chronic Lymphocytic Leukemia Coverage from Every Angle

Recent News

COVID-19 Infection Reported in Chinese Patient With CLL
Cellular Polarization and Its Impact on Growth of CLL Cells
Venetoclax Therapy and Attainment of Undetectable Minimal Residual Disease in CLL
Machine Modeling as a Predictive Tool for Infection Risk in Patients With CLL
First-Line Treatment With Four-Drug Regimen in Young Patients With CLL
Genomic Analyses May Predict Treatment Outcomes in Patients With CLL
CAPTIVATE Trial of First-Line Ibrutinib Plus Venetoclax in CLL
Dynamics of DNA Methylation in CLL Patients Treated With Chemoimmunotherapy
Targeting the B-Cell Receptor With Mithramycin Analogs in CLL
Study Finds Zanubrutinib Active in CLL or Small Lymphocytic Lymphoma
Results of Phase III SEQUOIA Trial of Zanubrutinib in CLL
Early-Phase Results With CD19-Directed Immunotherapy for CLL
Early Results With Chemotherapy-Free Triplet Regimen in Resistant CLL
Ibrutinib and Venetoclax in Treatment of Resistant CLL
Proof-of-Concept Trial of BTK Inhibitor in Advanced B-Cell Malignancies
ASH 2019: Extended Analysis of MURANO Trial of Venetoclax/Rituximab in CLL
ASH 2019: First-Line Ibrutinib and Venetoclax in Previously Treated CLL
ASH 2019: Updated Trial Results With Ibrutinib and Rituximab in CLL
ASH 2019: Acalabrutinib Combination Therapy and Monotherapy in Treatment-Naive CLL
ASH 2019: Acalabrutinib Combination Therapy for Previously Untreated CLL
Study Reports Early-Stage Impairment of Neutrophil Activity With Ibrutinib for CLL
FDA Approves Indication for Acalabrutinib in Chronic Lymphocytic Leukemia
Prognostic Value of Residual Lymphadenopathy After Chemoimmunotherapy for CLL
Weight Gain With Ibrutinib Treatment in Patients With CLL
Aging and Stereotypic B-Cell Receptors Associated With CLL
Using Minimal Residual Disease Detection to Monitor Outcomes in CLL Treatment
First-in-Human Study of CD200 Blockade With Samalizumab in CLL
Update on Resistance to Targeted Therapies in CLL

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.